Key result
Recombinant t-PA and bradykinin-stimulated endogenous t-PA release significantly reduced ex vivo thrombus area under low and high shear conditions (P<0.001 and P=0.03, respectively).
Why the study?
Does exogenous or endogenous tissue plasminogen activator (t-PA) reduce ex vivo thrombus formation in healthy volunteers?
Population
20 healthy volunteers
Comparison
Extracorporeal administration of recombinant… vs Saline (0 ng/mL t-PA) or placebo
Design
RCT, randomized cross-over, double-blind
Authors
Loading...
t-PA augmentation limits thrombus formation; confirms endogenous fibrinolysis as a modifiable target and supports patient trials.
RCT (n=20)
Double-blind
cross-over
Does exogenous or endogenous tissue plasminogen activator (t-PA) reduce ex vivo thrombus formation in healthy volunteers?
p-value: p=<0.001
Endogenous t-PA release, particularly when augmented by enalapril, enhances fibrinolysis and limits thrombus formation in an ex vivo clinical model.
Lucking et al. (2013) conducted an RCT in Healthy volunteers (n=20). Recombinant t-PA or intra-arterial bradykinin with/without oral enalapril vs. Placebo or saline was evaluated on Ex vivo thrombus area under low and high shear conditions (p=<0.001). Recombinant t-PA and bradykinin-stimulated endogenous t-PA release significantly reduced ex vivo thrombus area under low and high shear conditions (P<0.001 and P=0.03, respectively).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: